pathology | Demonstrated benefit and harm | k | |||
---|---|---|---|---|---|
lung cancer (metastatic) | versus No demonstrated result for efficacy | 1 trial | meta-analysis | ||
lung cancer (metastatic) | versus placebo durvalumab superior to placebo in terms of PFS in PACIFIC, 2017 (maintenance patients) | 1 trial | meta-analysis | ||
urothelial carcinoma (advanced) | versus No demonstrated result for efficacy | 1 trial | meta-analysis |